Eligibility for icosapent ethyl in a French population of coronary outpatients with type 2 diabetes

Abstract

Introduction We determined eligibility for icosapent ethyl (EPA) treatment in coronary artery disease (CAD). Material and methods Consecutive patients with type 2 diabetes and CAD were prospectively included from 03/2019 to 12/2020. Results 574 patients were included; mean age 71 years, 81% males, with a high prevalence of other risk factors (81% hypertension). Mean lipid-density lipoprotein cholesterol was 85 mg/dl, mean glycated hemoglobin HbA1c 7.1%, mean triglycerides 148 mg/dl; 82% received statins. Based on National Lipid Association criteria, 31% would be eligible for EPA. Conclusions In this contemporary survey in consecutive, unselected CAD patients in daily practice, almost a third would be potentially eligible for EPA.

Keywords

• cardiovascular disease
• icosapent ethyl (epa)
• medical therapy
• triglycerides
• diabetes mellitus